Amir Elstein - Teva Pharmaceutical Insider

TEVAN -- Mexico Stock  

MXN 443.47  6.53  1.45%

Vice Chairman of the Board
Mr. Amir Elstein is Independent Director of the Company. Mr. Elstein rejoined the Board of Directors in 2009. From January 2014 to July 2014, he served as Vice Chairman of the Board of Directors of Teva. Mr. Elstein serves as Chairman of the Board of Tower Semiconductor Ltd., Chairman of the Board of Governors of the Jerusalem College of Engineering and Chairman of the Board of the Israel Democracy Institute. Mr. Elstein also serves as Chairman andor as a member of the board of directors of several academic, scientific, educational, social and cultural institutions. Mr. Elstein served as the Chairman of the Board of Directors of Israel Corporationrationration from 2010 to 2013. From 2004 to 2008, Mr. Elstein was a member of Tevas senior management, where his most recent position was Executive Vice President, Global Pharmaceutical Resources. From 1995 to 2004, Mr. Elstein served on Tevas Board of Directors. Prior to joining Teva as an executive in 2004, Mr. Elstein held a number of executive positions at Intel Corporationrationration, most recently as General Manager of Intel Electronics Ltd., an Israeli subsidiary of Intel Corporationrationration. Mr. Elstein received a B.Sc. in physics and mathematics from the Hebrew University in Jerusalem, an M.Sc. in solid state physics from the Hebrew University and a diploma in senior business management from the Hebrew University.
Age: 61  Chairman Since 2014      
972 3 914 8171  http://www.tevapharm.com
Elstein?s leadership positions in various international corporations, including his experience as a chairman in international public companies and his service as an executive officer at Teva and other companies, provides global business management and pharmaceutical expertise.

Management Efficiency

The company has return on total asset (ROA) of 2.96 % which means that it generated profit of $2.96 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (57.14) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 30.75 B in total debt with debt to equity ratio (D/E) of 152.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Teva Pharmaceutical Industries Limited has Current Ratio of 0.98 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical operates under Drug Manufacturers - Specialty Generic classification in Mexico and traded on Mexico Stock Exchange. It employs 51792 people.Teva Pharmaceutical Industries Limited (TEVAN) is traded on Mexico Stock Exchange in Mexico. It is located in 5 Basel Street and employs 51,792 people.

Teva Pharmaceutical Leadership Team

Nechemia Peres, Director, MBA
Moshe Many, Director, Ph.D
Roger Abravanel, Director, MBA
Richard Daniell, President
Eyal Desheh, President, MBA
Mark Sabag, President
Richard Lerner, Director, Ph.D
Galia Maor, Director, Ph.D
Gianfranco Nazzi, President
Carlo Notaristefani, CEO, Ph.D
Iris BeckCodner, President, MBA
Brendan OGrady, President, MBA
JeanMichel Halfon, Director, MBA
Michael Hayden, President, Ph.D
Gabrielle Sulzberger, Director, MBA
Dipankar Bhattacharjee, President, MBA
Erez Vigodman, CEO
Yitzhak Peterburg, Director
Hafrun Fridriksdottir, President
Joseph Nitzani, Director, MBA
Timothy Wright, Executive
Perry Nisen, Director
Isaac Abravanel, President
Sigurdur Olafsson, CEO
David Stark, Executive
Murray Goldberg, Director, MBA
Dan Propper, Director
Ory Slonim, Director
Michael McClellan, President
Kevin Mannix, President
Amir Elstein, Chairman
Kaare Schultz, CEO
Dan Suesskind, Director, MBA
Arie Belldegrun, Director, Ph.D
Richard Egosi, President, MBA
Sol Barer, Director, Ph.D
Jean Halfon, Director
Sven Dethlefs, President, Ph.D
Robert Koremans, CEO, Ph.D
Gerald Lieberman, Director
Roberto Mignone, Director, MBA
Rosemary Crane, Director, MBA

Stock Performance Indicators

Current Sentiment - TEVAN

Teva Pharmaceutical Investor Sentiment
Macroaxis portfolio users are evenly split in their outlook on investing in Teva Pharmaceutical Industries Limited. What is your outlook on investing in Teva Pharmaceutical Industries Limited? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
C   
Purchased over 40 shares of
few hours ago
Traded for 67.0
ITTOF   
Purchased over 100 shares of
few hours ago
Traded for 23.2
GOOG   
Purchased few shares of
few hours ago
Traded for 1188.8199
CRM   
Purchased over 20 shares of
few hours ago
Traded for 147.61
GOOG   
Purchased few shares of
few hours ago
Traded for 1188.8199
Also please take a look at World Market Map. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.